Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Clinical Investigation

• Publication date

  2017-06-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1172/JCI93465PMID 28628033PMCID PMC5490764
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease

  2017cited by this paper
• Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.

  2017cited by this paper
• Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy‐proven nonalcoholic fatty liver disease: A prospective study

  2016cited by this paper
• Ventriculoperitoneal shunt tube infection and changing pattern of antibiotic sensitivity in neurosurgery practice: Alarming trends.

  2016cited by this paper
• Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study

  2016cited by this paper
• MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.

  2016cited by this paper
• Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study

  2016cited by this paper
• Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations.

  2016cited by this paper
• Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study

  2015cited by this paper
• Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non‐invasive diagnosis of advanced fibrosis in biopsy‐proven non‐alcoholic fatty liver disease: a prospective study

  2015cited by this paper
• The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH.

  2015cited by this paper
• Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

  2015cited by this paper
• Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)

  2015cited by this paper
• The Epidemiology of Cirrhosis in the United States: A Population-based Study

  2015cited by this paper
• Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

  2015cited by this paper
• Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults

  2015cited by this paper
• Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

  2015cited by this paper
• Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study.

  2015cited by this paper
• Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

  2015cited by this paper
• TM 6 SF 2 rs 58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease

  2014cited by this paper
• TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

  2014cited by this paper
• Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study

  2014cited by this paper
• Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.

  2014cited by this paper
• The global NAFLD epidemic

  2013cited by this paper
• Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography.

  2013cited by this paper
• Association between novel MRI‐estimated pancreatic fat and liver histology‐determined steatosis and fibrosis in non‐alcoholic fatty liver disease

  2013cited by this paper
• Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.

  2013cited by this paper
• Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials

  2013cited by this paper
• Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis

  2013cited by this paper
• Correlation between liver histology and novel magnetic resonance imaging in adult patients with non‐alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD

  2012cited by this paper
• The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.

  2012cited by this paper
• Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial

  2012cited by this paper
• Does this patient with liver disease have cirrhosis?

  2012cited by this paper
• Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis

  2012cited by this paper
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012influential reference
• Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012cited by this paper
• Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy

  2011cited by this paper
• Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

  2011cited by this paper
• Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.

  2011cited by this paper
• Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

  2011cited by this paper
• Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

  2011cited by this paper
• The association of genetic variability in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease

  2010cited by this paper
• Histopathology of nonalcoholic fatty liver disease.

  2010cited by this paper
• Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease.

  2010cited by this paper
• Heritability of nonalcoholic fatty liver disease.

  2009cited by this paper
• Histopathology of non-alcoholic fatty liver disease.

  2009cited by this paper
• Genetic variation in PNPLA 3 confers susceptibility to nonalcoholic fatty liver disease

  2009cited by this paper
• Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

  2008cited by this paper
• Liver cirrhosis.

  2008cited by this paper
• Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease.

  2006cited by this paper
• Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease

  2001cited by this paper
• Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds.

  2000cited by this paper
• [Liver cirrhosis].

  1989influential reference

• The simple multivariable model for predicting liver fibrosis in Vietnamese male adults: a combination of Bayesian model averaging and stepwise method

  2026influential citation
• Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease

  2025cites this paper
• Association of oxidative balance score with incident cardiovascular disease in patients with type 2 diabetes: findings of the UK Biobank study

  2025cites this paper
• Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends

  2025cites this paper
• Cardiovascular-kidney-metabolic: Hype or a focus on front-line health?

  2025cites this paper
• Ganoapplanilactone C from Ganoderma applanatum Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease via AMPK/mTOR-Mediated Lipid Regulation in Zebrafish

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention

  2025cites this paper
• Head-to-head comparison of MASH resolution index versus FAST for non-invasive prediction of resolution of MASH on biopsy.

  2025cites this paper
• Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD

  2025cites this paper
• Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment

  2025cites this paper
• An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease.

  2024cites this paper
• Prevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD.

  2024cites this paper
• The contribution of genetics and epigenetics to MAFLD susceptibility

  2024cites this paper
• Nature and nurture in familial aggregation of steatotic liver disease.

  2024cites this paper
• MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH

  2024cites this paper
• NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  2024cites this paper
• Natural history and progression of metabolic dysfunction-associated steatotic liver disease.

  2024cites this paper
• MASLD- Global prevalence, pathophysiological processes and management pathways- tackling a complex problem

  2024cites this paper
• Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti.

  2024cites this paper
• Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options

  2024cites this paper
• Risk of major adverse liver outcomes among first‐degree relatives of individuals with MASLD

  2024influential citation
• Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies

  2024cites this paper
• Resveratrol in disease prevention and health promotion: A role of the gut microbiome

  2023influential citation
• MASLD co-aggregates with HCC in families-names change, fa(c)ts remain

  2023cites this paper
• What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?

  2023cites this paper
• Natural history of metabolic dysfunction-associated steatotic liver disease.

  2023cites this paper
• A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma

  2023cites this paper
• Effect of Punica granatum extract supplementation in patients with liver cirrhosis: A randomized, double‐blind, placebo‐controlled trial

  2023cites this paper
• Familial clustering of nonalcoholic fatty liver disease in first‐degree relatives of adults with lean nonalcoholic fatty liver disease

  2023cites this paper
• A Current Approach to Non-Alcoholic Steatohepatitis in Type 2 Diabetes Mellitus Patients

  2023cites this paper
• Familial Coaggregation of MASLD with Hepatocellular Carcinoma and Adverse Liver Outcomes: Nationwide Multigeneration Cohort Study.

  2023cites this paper
• Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions

  2023cites this paper
• Towards precision medicine in non-alcoholic fatty liver disease

  2023cites this paper
• Trends in the incidence of cirrhosis in global from 1990 to 2019: A joinpoint and age‐period‐cohort analysis

  2023cites this paper
• Identification of Basement Membrane Genes and Related Molecular Subtypes in Nonalcoholic Fatty Liver Disease

  2023cites this paper
• Advances in the genetics of nonalcoholic fatty liver disease

  2023cites this paper
• Letter: deciphering the complexities of chronic liver disease epidemiology through a directed acyclic graph (DAG)

  2023cites this paper
• Editorial: first‐degree relatives of Mexican Americans with HCC are at increased risk of significant fibrosis—authors' reply

  2023cites this paper
• Proposition d’un parcours de soin pour les patients à risque de stéatohépatite non-alcoolique avec fibrose avancée : consensus DELPHI

  2023cites this paper
• Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment

  2023cites this paper
• AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

  2023cites this paper
• Prevalence and factors associated with liver fibrosis among first‐degree relatives of Mexican Americans with hepatocellular carcinoma

  2023cites this paper
• Liver fibrosis for the dermatologist: a review.

  2022cites this paper
• Non-alcoholic fatty liver disease and the impact of genetic, epigenetic and environmental factors in the offspring

  2022cites this paper
• Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease

  2022cites this paper
• Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials

  2022cites this paper
• Screening strategy for non-alcoholic fatty liver disease

  2022cites this paper
• Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment

  2022cites this paper
• Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease

  2022cites this paper
• The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease

  2022cites this paper
• Stratifying Non-alcoholic Steatohepatitis With the Non-invasive Ultrasound Markers Shear Wave Dispersion Slope and Shear Wave Velocity: An Animal Study.

  2022cites this paper
• Admixture mapping in African Americans identifies new risk loci for HCV-related cirrhosis.

  2022cites this paper
• Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease.

  2022cites this paper
• NAFLD: genetics and its clinical implications.

  2022cites this paper
• Redox-Unlockable Nanoparticle-Based MST1 Delivery System to Attenuate Hepatic Steatosis via the AMPK/SREBP-1c Signaling Axis

  2022cites this paper
• Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives

  2022cites this paper
• The role of microbiota in nonalcoholic fatty liver disease

  2022cites this paper
• Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis

  2022cites this paper
• Non-alcoholic Fatty Liver Disease and Depression: Evidence for Genotype × Environment Interaction in Mexican Americans

  2022cites this paper
• Referral care paths for non‐alcoholic fatty liver disease—Gearing up for an ever more prevalent and severe liver disease

  2021cites this paper
• KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

  2021cites this paper
• Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.

  2021cites this paper
• Management of non-alcoholic fatty liver disease

  2021cites this paper
• The interplay between non-alcoholic fatty liver disease and innate immunity in hepatitis B virus patients

  2021cites this paper
• The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk

  2021cites this paper
• Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates

  2021cites this paper
• Natural History of NAFLD

  2021cites this paper
• Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes

  2021cites this paper
• Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review

  2021cites this paper
• Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease

  2021cites this paper
• Nonalcoholic Fatty Liver Disease in Children: Spectrum and Consequences

  2021cites this paper
• The impact of genetic risk on liver fibrosis in non‐alcoholic fatty liver disease as assessed by magnetic resonance elastography

  2021cites this paper
• Mechanisms and disease consequences of nonalcoholic fatty liver disease.

  2021cites this paper
• The Role of the Microbiome in Liver Cancer

  2021cites this paper
• Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

  2021cites this paper
• Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship

  2021cites this paper
• Therapeutic Approaches for Nonalcoholic Steatohepatitis ( NASH )

  2021cites this paper
• Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests

  2021cites this paper
• Awareness, Knowledge, and Misperceptions Related to Nonalcoholic Fatty Liver Disease in a Community Sample of Mexican-Origin Women: A Mixed Methods Study

  2021cites this paper
• Antifibrotic Effects of Kangxian Ruangan Capsule on Rats with Nonalcoholic Fatty Liver Fibrosis and Hepatic Stellate Cells through Regulation of TGF-β and TLR4 Signaling Pathways

  2021cites this paper
• Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa.

  2021cites this paper
• MAFLD-Epidemiology, Natural History, Outcomes and Prevention

  2021cites this paper
• Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease.

  2021cites this paper
• HCC in metabolic syndrome: current concepts and future directions

  2021cites this paper
• Genetic Polymorphisms and Clinical Features in Diabetic Patients With Fatty Liver: Results From a Single-Center Experience in Southern Italy

  2021cites this paper
• Genetic predictors and pathophysiological features of non-alcoholic fat liver disease

  2021cites this paper
• Biomarkers in Fatty Liver Disease-Here is the Skinny.

  2021cites this paper
• Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity

  2021cites this paper
• The advantages of physical exercise as a preventive strategy against NAFLD in postmenopausal women

  2021cites this paper
• Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem

  2021cites this paper
• The Beneficial Additive Effect of Silymarin in Metformin Therapy of Liver Steatosis in a Pre-Diabetic Model

  2021cites this paper
• Intestinal Barrier and Permeability in Health, Obesity and NAFLD

  2021cites this paper
• Circulating non-coding RNAs as potential diagnostic biomarkers in liver diseases

  2021cites this paper
• Nonalcoholic Fatty Liver Disease in Children.

  2021cites this paper
• Metabolic Associated Fatty Liver Disease in Children—From Atomistic to Holistic

  2021cites this paper
• Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome

  2020cites this paper
• Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease.

  2020cites this paper
• Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting

  2020cites this paper
• Journal Pre-proof Ready for population screening?

  2020cites this paper
• The Natural History of NAFLD: Environmental vs. Genetic Risk Factors

  2020cites this paper